Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Resistance to anti-HER2 therapy in breast cancer remains a major obstacle in the clinic. Here the authors performed a CRISPR-selective vulnerability screen to identify transaldoloase as a target that is synthetically lethal with HER2 inhibition in breast cancer cells.

Guardado en:

Detalles Bibliográficos
Autores principales:	Yi Ding, Chang Gong, De Huang, Rui Chen, Pinpin Sui, Kevin H. Lin, Gehao Liang, Lifeng Yuan, Handan Xiang, Junying Chen, Tao Yin, Peter B. Alexander, Qian-Fei Wang, Er-Wei Song, Qi-Jing Li, Kris C. Wood, Xiao-Fan Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/3b4653d4e9534695875c3adfe802cb21
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3b4653d4e9534695875c3adfe802cb21
record_format	dspace
spelling	oai:doaj.org-article:3b4653d4e9534695875c3adfe802cb212021-12-02T14:40:32ZSynthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers10.1038/s41467-018-06651-x2041-1723https://doaj.org/article/3b4653d4e9534695875c3adfe802cb212018-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-06651-xhttps://doaj.org/toc/2041-1723Resistance to anti-HER2 therapy in breast cancer remains a major obstacle in the clinic. Here the authors performed a CRISPR-selective vulnerability screen to identify transaldoloase as a target that is synthetically lethal with HER2 inhibition in breast cancer cells.Yi DingChang GongDe HuangRui ChenPinpin SuiKevin H. LinGehao LiangLifeng YuanHandan XiangJunying ChenTao YinPeter B. AlexanderQian-Fei WangEr-Wei SongQi-Jing LiKris C. WoodXiao-Fan WangNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Yi Ding Chang Gong De Huang Rui Chen Pinpin Sui Kevin H. Lin Gehao Liang Lifeng Yuan Handan Xiang Junying Chen Tao Yin Peter B. Alexander Qian-Fei Wang Er-Wei Song Qi-Jing Li Kris C. Wood Xiao-Fan Wang Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
description	Resistance to anti-HER2 therapy in breast cancer remains a major obstacle in the clinic. Here the authors performed a CRISPR-selective vulnerability screen to identify transaldoloase as a target that is synthetically lethal with HER2 inhibition in breast cancer cells.
format	article
author	Yi Ding Chang Gong De Huang Rui Chen Pinpin Sui Kevin H. Lin Gehao Liang Lifeng Yuan Handan Xiang Junying Chen Tao Yin Peter B. Alexander Qian-Fei Wang Er-Wei Song Qi-Jing Li Kris C. Wood Xiao-Fan Wang
author_facet	Yi Ding Chang Gong De Huang Rui Chen Pinpin Sui Kevin H. Lin Gehao Liang Lifeng Yuan Handan Xiang Junying Chen Tao Yin Peter B. Alexander Qian-Fei Wang Er-Wei Song Qi-Jing Li Kris C. Wood Xiao-Fan Wang
author_sort	Yi Ding
title	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
title_short	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
title_full	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
title_fullStr	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
title_full_unstemmed	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
title_sort	synthetic lethality between her2 and transaldolase in intrinsically resistant her2-positive breast cancers
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/3b4653d4e9534695875c3adfe802cb21
work_keys_str_mv	AT yiding syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT changgong syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT dehuang syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT ruichen syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT pinpinsui syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT kevinhlin syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT gehaoliang syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT lifengyuan syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT handanxiang syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT junyingchen syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT taoyin syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT peterbalexander syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT qianfeiwang syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT erweisong syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT qijingli syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT kriscwood syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers AT xiaofanwang syntheticlethalitybetweenher2andtransaldolaseinintrinsicallyresistanther2positivebreastcancers
_version_	1718390231068049408

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers

Ejemplares similares